Antinuclear antibodies in chronic psychotic patients treated with chlorpromazine.
The authors found a significantly higher incidence of antinuclear antibodies (ANA) and positive lupus erythematosus cell tests in chronic psychotic patients who received 400 mg a day or more of chlorpromazine (CPZ) for at least 7 weeks than in those who had taken 50 to 300 mg a day for varying periods or those who had received no CPZ for at least 3 months. Despite the high incidence of ANA, there was no observed development of lupuslike syndrome. The authors suggest that CPZ in high doses may induce ANA in humans.
D000328:Adult; D000974:Antibodies, Antinuclear; D002746:Chlorpromazine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009504:Neutrophils; D011618:Psychotic Disorders / Q000188:drug therapy / Q000276:immunology*
D000974:Antibodies, Antinuclear; D002746:Chlorpromazine